EGFR and squamous cell carcinoma: Current progress include more efficient chemotherapy compounds for so-called non-squamous carcinomas, including the multifolate inhibitor pemetrexed (21), and smaller subgroups with molecular changes such as EGFR mutations and ALK rearrangements that significantly predict the effect of biological targeted therapies (22, 23).